Immunome Valuation Multiples

Immunome Overview

About Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Founded

2006

HQ

Employees

118

Website

immunome.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $6M

EBITDA: ($235M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Immunome Financials

Immunome reported last 12-month revenue of $6M and negative EBITDA of ($235M).

In the same LTM period, Immunome generated $6M in gross profit, ($235M) in EBITDA losses, and had net loss of ($224M).

Immunome P&L

In the most recent fiscal year, Immunome reported revenue of $7M and EBITDA of ($221M).

Immunome expects next 12-month revenue of XXX and NTM EBITDA of XXX

Immunome Stock Performance

Immunome has current market cap of $2B, and enterprise value of $2B.

Immunome's stock price is $20.95.

Immunome Valuation Multiples

Immunome trades at 318.6x EV/Revenue multiple, and (8.7x) EV/EBITDA.

Immunome Financial Valuation Multiples

As of March 18, 2026, Immunome has market cap of $2B and EV of $2B.

Equity research analysts estimate Immunome's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Immunome has a P/E ratio of (10.3x).

Immunome Margins & Growth Rates

Immunome's revenue in the last 12 month grew by 225%.

Immunome's revenue per employee in the last FY averaged $0.1M.

Immunome's rule of 40 is (3432%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Immunome's rule of X is (3094%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Immunome Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Immunome M&A Activity

Immunome acquired XXX companies to date.

Last acquisition by Immunome was on XXXXXXXX, XXXXX. Immunome acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Immunome Investment Activity

Immunome invested in XXX companies to date.

Immunome made its latest investment on XXXXXXXX, XXXXX. Immunome invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).